BioCryst Pharma Analyst Price Targets - Benzinga

BioCryst Pharmaceuticals Inc

BCRXNASDAQ

Trade with Public

Trade with Public

$8.46

-0.0136-0.16%

마지막 업데이트: Nov 2, 8:08 AM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

BioCryst Pharma Analyst Price Targets - Benzinga

BioCryst Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioCryst Pharma (BCRX).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

3S.Buy

7Buy

2Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$21Upside to Avg. PT+144.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	JP Morgan	Jessica Fye	PT Raise	Neutral	$12→$13
Sep 10, 2026	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$13→$11
Sep 8, 2026	Needham	Serge Belanger	Maintained	Buy	$16
Aug 6, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$14→$13
Aug 6, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$21→$20
Jul 13, 2026	JP Morgan	Jessica Fye	Reinstates	Neutral	$12
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$13→$14
Jun 30, 2026	HC Wainwright & Co.	Andrew S. Fein	Maintained	Buy	$32
Jun 30, 2026	Cantor Fitzgerald	Steven Seedhouse	PT Raise	Overweight	$27→$29
May 7, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$25→$28
May 7, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$22→$21
May 6, 2026	Needham	Serge Belanger	PT Cut	Buy	$18→$16
Jan 30, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$14→$13
Dec 15, 2025	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$30→$32
Nov 5, 2025	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$27→$25
Nov 4, 2025	Barclays	Gena Wang	PT Cut	Equal-Weight	$11→$9
Nov 4, 2025	Needham	Serge Belanger	PT Cut	Buy	$20→$18
Oct 15, 2025	TD Cowen	Stacy Ku	Reinstates	Buy	$30
Oct 15, 2025	Cantor Fitzgerald	Steven Seedhouse	PT Raise	Overweight	$24→$26
Oct 15, 2025	JMP Securities	Jonathan Wolleben	PT Raise	Market Outperform	$17→$27

Analyst Ratings News

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

Bank of America upgrades Pharvaris to Buy with a new price target, citing reduced clinical risk for deucrictibant in hereditary angioedema despite market competition.

Vandana Singh

PRO
JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13

JP Morgan analyst Jessica Fye maintains BioCryst Pharma (NASDAQ:BCRX) with a Neutral and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11

RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $16 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $14 to $13.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $20

Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $21 to $20.

Benzinga Newsdesk